Show simple item record

dc.contributor.authorRowe, Jacob M
dc.contributor.authorBuck, Georgina
dc.contributor.authorBurnett, Alan K
dc.contributor.authorChopra, Rajesh
dc.contributor.authorWiernik, Peter H
dc.contributor.authorRichards, Susan M
dc.contributor.authorLazarus, Hillard M
dc.contributor.authorFranklin, Ian M
dc.contributor.authorLitzow, Mark R
dc.contributor.authorCiobanu, Niculae
dc.contributor.authorPrentice, H Grant
dc.contributor.authorDurrant, I Jill
dc.contributor.authorTallman, Martin S
dc.contributor.authorGoldstone, Anthony H
dc.date.accessioned2009-07-29T12:03:11Z
dc.date.available2009-07-29T12:03:11Z
dc.date.issued2005-12-01
dc.identifier.citationInduction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. 2005, 106 (12):3760-7 Blooden
dc.identifier.issn0006-4971
dc.identifier.pmid16105981
dc.identifier.doi10.1182/blood-2005-04-1623
dc.identifier.urihttp://hdl.handle.net/10541/75824
dc.description.abstractThe international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL. All patients received identical induction therapy, and 91% achieved complete remission (CR). Patients 50 years of age or younger with a compatible sibling were assigned to undergo allogeneic transplantation; the others were randomly assigned to autologous transplantation or to consolidation/maintenance therapy for 2.5 years. Patients who did not achieve CR after induction had an overall survival rate of 5% compared with 45% for patients who achieved CR. Factors at diagnosis predictive of overall survival and disease-free survival were age (P = .001), white blood cell count less than 30 x 10(9)/L for B lineage or less than 100 x 10(9)/L for T lineage (P = .001) and immunophenotype, T lineage versus B lineage (P = .001). The data demonstrate that achieving CR with induction therapy is indispensable for long-term survival in adult patients with ALL. Furthermore, with a response rate greater than 90%, the induction regimen was highly efficacious as remission-inducing therapy. This large database has validated several previously identified independent prognostic factors in ALL, such as age, white blood cell count at presentation, cytogenetics, and immunophenotype. However, the achievement of CR within 4 weeks does not appear to be an independent prognostic factor.
dc.language.isoenen
dc.subject.meshAdult
dc.subject.meshAge Factors
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBone Marrow Transplantation
dc.subject.meshDisease-Free Survival
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPhiladelphia Chromosome
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subject.meshPrognosis
dc.subject.meshRemission Induction
dc.subject.meshSurvival Analysis
dc.subject.meshTreatment Outcome
dc.titleInduction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.en
dc.typeArticleen
dc.contributor.departmentDepartment of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa 31096, Israel. rowe@jimmy.harvard.eduen
dc.identifier.journalBlooden
html.description.abstractThe international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL. All patients received identical induction therapy, and 91% achieved complete remission (CR). Patients 50 years of age or younger with a compatible sibling were assigned to undergo allogeneic transplantation; the others were randomly assigned to autologous transplantation or to consolidation/maintenance therapy for 2.5 years. Patients who did not achieve CR after induction had an overall survival rate of 5% compared with 45% for patients who achieved CR. Factors at diagnosis predictive of overall survival and disease-free survival were age (P = .001), white blood cell count less than 30 x 10(9)/L for B lineage or less than 100 x 10(9)/L for T lineage (P = .001) and immunophenotype, T lineage versus B lineage (P = .001). The data demonstrate that achieving CR with induction therapy is indispensable for long-term survival in adult patients with ALL. Furthermore, with a response rate greater than 90%, the induction regimen was highly efficacious as remission-inducing therapy. This large database has validated several previously identified independent prognostic factors in ALL, such as age, white blood cell count at presentation, cytogenetics, and immunophenotype. However, the achievement of CR within 4 weeks does not appear to be an independent prognostic factor.


This item appears in the following Collection(s)

Show simple item record